Fiscal Receipts

Senate LDA lobbying filing

PFIZER INC.

Registrant: PFIZER INC. Year: 2026 Period: First Quarter Type: Q1

View on lda.senate.gov ↗

Reported income

not reported

Reported expenses

$4.42M

Tracked program mentions4

Quoted activity text is clipped to a short extract; each filing’s full description is under Lobbying activities below.

  • Amphibious Combat Vehicle Family of Vehicles2025matched: “2025”PE code cited directly

    Vaccine Coverage Pediatric Immunization Schedule Vaccine Injury Compensation Program Executive Order 14297…

  • Explosive Ordnance Disposal Equip5509matched: “5509”PE code cited directly

    Vaccine Coverage Pediatric Immunization Schedule Vaccine Injury Compensation Program Executive Order 14297…

  • Making, Maintaining, Supply Chain and Logistics0602025Ematched: “Supply|Chain”matched 2+ title words

    International Supply Chain Market Access Most Favored Nation Policies Foreign Freeriding Issues Non-Tariff Trade…

  • SPQ-9B Radar2026matched: “2026”PE code cited directly

    Vaccine Coverage Pediatric Immunization Schedule Vaccine Injury Compensation Program Executive Order 14297…

Lobbying activities4

  • Copyright/Patent/TrademarkCPT

    Intellectual Property Protections

  • Health IssuesHCR

    Vaccine Coverage Pediatric Immunization Schedule Vaccine Injury Compensation Program Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 7837 - Most Favored Patient Act of 2026 Lyme Disease Issues 340B Issues Counterfeit Drugs Inflation Reduction Act (IRA) Prescription Drug User Fee Act (PDUFA) Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 3510 - Biosimilar Inspection Modernization Act of 2025

  • Medicare/MedicaidMMM

    Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Prescription Drug User Fee Act (PDUFA) 340B Issues Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage PBM Reform Counterfeit Drugs P.L. 117-169 - Inflation Reduction Act (IRA) of 2022 Drug Pricing Medicare/Medicaid Issues

  • Trade (domestic/foreign)TRD

    International Supply Chain Market Access Most Favored Nation Policies Foreign Freeriding Issues Non-Tariff Trade Barriers Competiveness Issues Trade Issues

Lobbyists7

  • ANGELA WILES
  • CATHERINE ROBINSON
  • EMILY MUELLER
  • FRANCISCO CARRILLO
  • JENNIFER WALTON
  • MATTHEW STROIA
  • STEPHEN CLAEYS

Source: U.S. Senate Lobbying Disclosure Act database. Dollar figures (underlined) cite the filing record on lda.senate.gov — click to view the citation. Amounts shown as “not reported” are absent from the filing itself.